Darlene Dobkowski

Navtemadlin monotherapy was safe and effective among patients with myelofibrosis who were relapsed or refractory to treatment with JAK inhibitors.

Experts discussed what other information is needed to understand how best to use Kisqali in treating patients in the adjuvant setting with early breast cancer.

Camizestrant with Kisqali is effective and tolerable for ER-positive/HER2-negative advanced breast cancer, with a median PFS of 8.1 months for both doses.

Patients with luminal B and HER2E breast cancer subtypes may have a greater PFS benefit with ribociclib plus endocrine therapy vs combination chemotherapy.

The effect of a 100-mg dose of bezuclastinib occurred with a favorable safety and tolerability profile in patients with non-advanced systemic mastocytosis.

This marks the first mesenchymal stromal cell therapy approved by the FDA for children with acute graft versus host disease.

Ribociclib was approved for HR-positive, HER2-negative early breast cancer based on the NATALEE trial's significant invasive disease-free survival results.

Targeting the estrogen receptor and HER2 pathways improved progression-free survival in patients with HR-positive, HER2-positive metastatic breast cancer.

FDA approved Braftovi, Erbitux, and mFOLFOX6 for BRAF V600E mutation-positive metastatic colorectal cancer.

Darzalex addition to VRd improved MRD negativity and PFS in transplant-ineligible multiple myeloma patients.